XEGLYZE
Peakabametapir
NDATOPICALLOTION
Approved
Jul 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
5
Data completeness
4/8 — Partial
XEGLYZE (abametapir) is (5,5’-dimethyl 2,2’-bipyridinyl) is a metalloproteinase inhibitor. First approved in 2020.
Drug data last refreshed 5h ago · AI intelligence enriched 4w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XEGLYZE (abametapir) is a topical lotion that treats head lice infestation by inhibiting metalloproteinases critical to louse egg development and survival. This small-molecule approach offers a novel mechanism of action distinct from traditional pediculicides. The drug represents a new therapeutic option for patients seeking effective lice treatment.
Peak8.2 years to LOE
Product is in peak commercial phase with no reported competitive pressure, suggesting a favorable market position for brand team expansion and revenue growth initiatives.
Mechanism of Action
(5,5’-dimethyl 2,2’-bipyridinyl) is a metalloproteinase inhibitor. Metalloproteinases have a role in physiological processes critical to egg development and survival of lice.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
Ovicidal Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation
Started May 2014
50 enrolled
Head Lice Infestation
A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation
Started Feb 2014
379 enrolled
Head Lice Infestation
Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation
Started Feb 2014
325 enrolled
Head Lice Infestation
Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion
Started Jan 2014
238 enrolled
Head Lice
Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion
Started Jan 2014
40 enrolled
Head Lice
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.